Journal
PEDIATRIC BLOOD & CANCER
Volume 54, Issue 4, Pages 649-651Publisher
WILEY
DOI: 10.1002/pbc.22378
Keywords
high-dose chemotherapy; PNETs; recurrence
Categories
Ask authors/readers for more resources
We summarize data presented on the use of high-dose chemotherapy (HDCT) with stem cell rescue for patients with recurrent medulloblastoma and other primitive neuroectodermal tumors as presented at an international consensus and state of the art workshop held in Milan in 2006 Eight, mainly institutional, studies were presented that included 159 patients who received HDCT of whom 22% were disease-free survivors at the time of reporting Of those receiving HDCT and who relapsed having received previous radiotherapy, 17 3% were disease-free survivors at the time of reporting. However, from the two national studies that reported results from the time of relapse, only 4 2% were event free survivors The outlook for previously irradiated patients with recurrent PNETs remains extremely poor and more effective therapeutic approaches are needed. Pediatr Blood Cancer 2010,54 649-651 (C) 2010 Wiley-Liss, Inc
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available